US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box
Zeidan AM, Gore SD, Davidoff AJ. US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box. Journal Of Clinical Oncology 2017, 35: jco.2017.74.310. PMID: 28787256, DOI: 10.1200/jco.2017.74.3104.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDrug LabelingErythropoiesisErythropoietinHematinicsHumansUnited StatesUnited States Food and Drug Administration